Repository logo
 
Publication

Incidence of postoperative residual neuromuscular blockade: a multicenter, observational study in Portugal (INSPIRE 2)

dc.contributor.authorEsteves, Simão
dc.contributor.authorBarros, Filinto Correia de
dc.contributor.authorNunes, Catarina S.
dc.contributor.authorPuga, Andreia
dc.contributor.authorGomes, Blandina
dc.contributor.authorAbelha, Fernando
dc.contributor.authorMachado, Humberto
dc.contributor.authorFerreira, Milene
dc.contributor.authorFernandes, Nuno
dc.contributor.authorVítor, Paula
dc.contributor.authorPereira, Sandra
dc.contributor.authorLapa, Teresa A.
dc.contributor.authorOliveira, Vítor Pinho
dc.date.accessioned2023-10-10T08:17:06Z
dc.date.available2023-10-10T08:17:06Z
dc.date.issued2023
dc.description.abstractBackground: Although the use of neuromuscular blocking agents (NMBAs) optimizes surgical conditions and facilitates tracheal intubation, it can lead to residual neuromuscular blockade (RNMB), with postoperative complications. This study aimed to assess RNMB incidence and management in Portugal. Methods: Prospective observational study of patients admitted for elective surgery requiring general anesthesia with nondepolarizing NMBAs between July 2018 and July 2019 at 10 Portuguese hospitals. The primary endpoint was the proportion of patients arriving at postanesthesia care unit (PACU) with a TOF ratio ,0.9. Results: A total of 366 patients were included, with a median age of 59 years, and 89.1% classified as ASA II or III. Rocuronium was the most used NMBA (99.5%). A total of 96.2% of patients received a reversal agent, 96.6% of which sugammadex and 3.4% neostigmine. Twenty patients displayed a TOF ratio ,0.9 at PACU arrival, representing an RNMB incidence of 5.5% (95% CI, 3.1%–7.8%). Only two patients displayed a TOF ratio ,0.7. RNMB incidence was 16.7% with neostigmine and 5.3% with sugammadex (P 5 .114). In patients with intraoperative neuromuscular blockade (NMB) monitoring, RNMB incidence was 5% (95% CI, 2%–8%), which varied significantly according to the type of monitoring (P 5 .018). Incidence of adverse events was 3.3% (2 severe and 10 moderate). Conclusions: The reported overall incidence of 5.5% is numerically lower than results from similar observational studies. An appropriate pharmacological neuromuscular reversal strategy, guided by quantitative neuromuscular monitoring, has the potential to achieve even better results, converting RNMB from an unusual to a very rare or even inexistent event.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationS. Esteves, F. Correia de Barros, C. .S Nunes, A. Puga, B. Gomes, F. Abelha, H. Machado, M. Ferreira, N. Fernandes, P. Vítor, S. Pereira, T. A. Lapa and V. Pinho-Oliveira (2023). “Incidence of postoperative residual neuromuscular blockade − A multicenter, observational study in Portugal (INSPIRE 2).” Porto Biomedical Journal, 8 (4): e225pt_PT
dc.identifier.doi10.1097/j.pbj.0000000000000225pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.2/15055
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherWolters Kluwerpt_PT
dc.relation.publisherversionhttps://journals.lww.com/pbj/fulltext/2023/08000/incidence_of_postoperative_residual_neuromuscular.2.aspxpt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.subjectGeneral anesthesiapt_PT
dc.subjectNeuromuscular blocking agentspt_PT
dc.subjectNeuromuscular reversal agentspt_PT
dc.subjectNeuromuscular monitoringpt_PT
dc.subjectResidual neuromuscular blockadept_PT
dc.titleIncidence of postoperative residual neuromuscular blockade: a multicenter, observational study in Portugal (INSPIRE 2)pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage7pt_PT
oaire.citation.startPage1pt_PT
oaire.citation.titlePorto Biomedical Journalpt_PT
person.familyNameEsteves
person.familyNameNunes
person.givenNameSimão
person.givenNameCatarina S.
person.identifier.ciencia-id3C17-E9CC-AE8F
person.identifier.ciencia-id691F-CDC2-E26A
person.identifier.orcid0000-0003-0305-1842
person.identifier.orcid0000-0002-8357-0994
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationadefc12a-73e9-4f08-ad9d-c1c82bc20927
relation.isAuthorOfPublicationcc3069ec-f930-455f-9226-b77e5d2dc14b
relation.isAuthorOfPublication.latestForDiscoverycc3069ec-f930-455f-9226-b77e5d2dc14b

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
pj9-8-e225.pdf
Size:
580.91 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.97 KB
Format:
Item-specific license agreed upon to submission
Description: